USP9X and malignant colon neoplasm: Fig 5 shows the log hazard ratios for overall survival outcomes of the 414 genes compared between nCounter and microarray data, with the red, green and blue dots indicating the 6, 49 and 359 genes having significant survival association in the two, one and neither platforms. For the six genes identified by both platforms, previous studies showed that CCND1 and S100A1can be used as biomarkers for colon cancer prognosis [30, 31], and the inhibition of USP9X might increase the tumor cell sensitivity to some chemotherapeutic agents [32, 33].